Pancreatic Cancer Research

ResearcherUniversity of PittsburghActive in the last 2 years

Aatur Dilip Singhi

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0003-3930-7096; OpenAlex author ID A5023598971, A5076238321. Sources: OpenAlex.

Their work

Papers
56 (first author 1, last author 2)
Trials
0
Grants
1
Labs led
1
Collaborators
217
Papers, trials and grants by year

2014: 2 papers · 2015: 2 papers · 2016: 1 grant · 2017: 5 papers · 2018: 4 papers · 2019: 5 papers · 2020: 8 papers · 2021: 7 papers · 2022: 4 papers · 2023: 6 papers · 2024: 3 papers · 2025: 5 papers · 2026: 5 papers

Papers 50 of 56

  1. Cigarette smoking drives earlier development of pancreatic adenocarcinoma among carriers of hereditary pancreatic cancer susceptibility genes. Co-author DOI 10.1016/j.pan.2026.05.004↗
  2. High-Sensitive Spatial Proteomics for Pancreatic Cancer Progression Analysis. Co-author DOI 10.1021/acs.analchem.5c01928↗
  3. Pancreatic Cancer Organoids Recapitulate Chemotherapy Response and Identify a Potent Cytotoxic T-Cell Population. Co-author DOI 10.1158/1078-0432.ccr-25-1110↗
  4. Development and Validation of a Computational Histology Artificial Intelligence-Powered Predictive Biomarker for Selection of Chemotherapy in Advanced Pancreat… Co-author DOI 10.1200/jco-25-02199↗
  5. KRAS Mutation Allele Frequency Dynamics in Plasma Extracellular Vesicles: Association with Survival in Localized Pancreatic Adenocarcinoma. Co-author DOI 10.1245/s10434-025-18633-7↗
  6. Implications of an Isolated Positive Vascular Groove After Whipple for Pancreatic Adenocarcinoma: A Single Institution, Retrospective Analysis. Co-author DOI 10.1002/jso.70052↗
  7. Optimizing Perioperative Management of Pancreatic Ductal Adenocarcinoma: Insights Into Modified FOLFIRINOX Relative Dose Intensity and CA 19-9 Dynamics. Co-author DOI 10.1002/jso.70057↗
  8. Multiplexed glycan immunofluorescence identification of pancreatic cancer cell subpopulations in both tumor and blood samples. Co-author DOI 10.1126/sciadv.adt0029↗
  9. SMAD4 Deficiency Promotes Pancreatic Cancer Progression and Confers Susceptibility to TGFβ Inhibition. Co-author DOI 10.1158/0008-5472.can-24-1970↗
  10. ASO Visual Abstract: KRAS Mutation Allele Frequency Dynamics in Plasma Extracellular Vesicles: Associations with Survival in Localized Pancreatic Adenocarcinoma Co-author DOI 10.1245/s10434-025-18842-0↗
  11. Impact of Neoadjuvant Therapy on Oncological Outcomes of Patients With Distal Pancreatic Adenocarcinoma. Co-author DOI 10.1002/jso.27856↗
  12. Reconstitution of human PDAC using primary cells reveals oncogenic transcriptomic features at tumor onset. Co-author DOI 10.1038/s41467-024-45097-2↗
  13. Pancreatic Cysts Greater Than 1 cm Are Associated With an Increased Risk for Developing Pancreatic Cancer in Individuals From Pancreatic-Cancer Prone Kindreds … Co-author DOI 10.1097/mpa.0000000000002312↗
  14. The use of angiotensin system inhibitors correlates with longer survival in resected pancreatic adenocarcinoma patients. Co-author DOI 10.1016/j.hpb.2022.12.002↗
  15. No survival benefit with suboptimal CA19-9 response: defining effective neoadjuvant chemotherapy in resectable or borderline resectable pancreatic cancer. Co-author DOI 10.1016/j.hpb.2023.01.016↗
  16. Development of an artificial intelligence-derived histologic signature associated with adjuvant gemcitabine treatment outcomes in pancreatic cancer. Co-author DOI 10.1016/j.xcrm.2023.101013↗
  17. A Novel HRD Signature Is Predictive of FOLFIRINOX Benefit in Metastatic Pancreatic Cancer. Co-author DOI 10.1093/oncolo/oyad178↗
  18. A Combined DNA/RNA-based Next-Generation Sequencing Platform to Improve the Classification of Pancreatic Cysts and Early Detection of Pancreatic Cancer Arising… Last author DOI 10.1097/sla.0000000000005904↗
  19. Impact of Recombinant Granulocyte Colony-Stimulating Factor During Neoadjuvant Therapy on Outcomes of Resected Pancreatic Cancer. Co-author DOI 10.6004/jnccn.2023.7070↗
  20. Adaptive Dynamic Therapy and Survivorship for Operable Pancreatic Cancer. Co-author DOI 10.1001/jamanetworkopen.2022.18355↗
  21. Tumor Size Differences Between Preoperative Endoscopic Ultrasound and Postoperative Pathology for Neoadjuvant-Treated Pancreatic Ductal Adenocarcinoma Predict … Last author DOI 10.1016/j.cgh.2020.11.041↗
  22. Loss of Rnf43 Accelerates Kras-Mediated Neoplasia and Remodels the Tumor Immune Microenvironment in Pancreatic Adenocarcinoma. Co-author DOI 10.1053/j.gastro.2021.12.273↗
  23. Histopathological tumour response scoring in resected pancreatic cancer following neoadjuvant therapy: international interobserver study (ISGPP-1). Co-author DOI 10.1093/bjs/znac350↗
  24. Neoadjuvant therapy versus upfront surgery for early-stage left-sided pancreatic adenocarcinoma: A propensity-matched analysis from a national cohort of distal… Co-author DOI 10.1002/jso.26267↗
  25. Amsterdam International Consensus Meeting: tumor response scoring in the pathology assessment of resected pancreatic cancer after neoadjuvant therapy. Co-author DOI 10.1038/s41379-020-00683-9↗
  26. Early detection of pancreatic cancer using DNA-based molecular approaches. Co-author DOI 10.1038/s41575-021-00470-0↗
  27. SMAD4 loss is associated with response to neoadjuvant chemotherapy plus hydroxychloroquine in patients with pancreatic adenocarcinoma. Co-author DOI 10.1111/cts.13029↗
  28. Detection of Chemotherapy-resistant Pancreatic Cancer Using a Glycan Biomarker, sTRA. Co-author DOI 10.1158/1078-0432.ccr-20-2475↗
  29. Outcomes of Neoadjuvant Chemotherapy Versus Chemoradiation in Localized Pancreatic Cancer: A Case-Control Matched Analysis. Co-author DOI 10.1245/s10434-020-09391-9↗
  30. A Pancreatic Cancer Multidisciplinary Clinic Eliminates Socioeconomic Disparities in Treatment and Improves Survival. Co-author DOI 10.1245/s10434-021-09594-8↗
  31. Pattern of Invasion in Human Pancreatic Cancer Organoids Is Associated with Loss of SMAD4 and Clinical Outcome. Co-author DOI 10.1158/0008-5472.can-19-1523↗
  32. Biomarkers and Strategy to Detect Preinvasive and Early Pancreatic Cancer: State of the Field and the Impact of the EDRN. Co-author DOI 10.1158/1055-9965.epi-20-0161↗
  33. A Randomized Phase II Preoperative Study of Autophagy Inhibition with High-Dose Hydroxychloroquine and Gemcitabine/Nab-Paclitaxel in Pancreatic Cancer Patients. Co-author DOI 10.1158/1078-0432.ccr-19-4042↗
  34. Novel ALK Fusion, PPFIBP1-ALK, in Pancreatic Ductal Adenocarcinoma Responsive to Alectinib and Lorlatinib. Co-author DOI 10.1200/po.19.00365↗
  35. CA19-9 Change During Neoadjuvant Therapy May Guide the Need for Additional Adjuvant Therapy Following Resected Pancreatic Cancer. Co-author DOI 10.1245/s10434-020-08468-9↗
  36. SMAD4 Loss is Associated with Response to Neoadjuvant Chemotherapy with Hydroxychloroquine in Patients with Pancreatic Adenocarcinoma Co-author DOI 10.21203/rs.3.rs-125334/v1↗
  37. Assessment of Response to Neoadjuvant Therapy Using CT Texture Analysis in Patients With Resectable and Borderline Resectable Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.2214/ajr.19.21152↗
  38. Imaging-Based Subtypes of Pancreatic Ductal Adenocarcinoma Exhibit Differential Growth and Metabolic Patterns in the Pre-Diagnostic Period: Implications for Ea… Co-author DOI 10.3389/fonc.2020.596931↗
  39. Histomorphology of pancreatic cancer in patients with inherited ATM serine/threonine kinase pathogenic variants. Co-author DOI 10.1038/s41379-019-0317-6↗
  40. Early Detection of Pancreatic Cancer: Opportunities and Challenges. Co-author DOI 10.1053/j.gastro.2019.01.259↗
  41. Prolactin Promotes Fibrosis and Pancreatic Cancer Progression. Co-author DOI 10.1158/0008-5472.can-18-3064↗
  42. Single-Cell Transcriptomics of Pancreatic Cancer Precursors Demonstrates Epithelial and Microenvironmental Heterogeneity as an Early Event in Neoplastic Progre… Co-author DOI 10.1158/1078-0432.ccr-18-1955↗
  43. The sTRA Plasma Biomarker: Blinded Validation of Improved Accuracy Over CA19-9 in Pancreatic Cancer Diagnosis. Co-author DOI 10.1158/1078-0432.ccr-18-3310↗
  44. Germline mutation prevalence in individuals with pancreatic cancer and a history of previous malignancy. Co-author DOI 10.1002/cncr.31242↗
  45. Systemic Depletion of Nerve Growth Factor Inhibits Disease Progression in a Genetically Engineered Model of Pancreatic Ductal Adenocarcinoma. First author DOI 10.1097/mpa.0000000000001090↗
  46. Overweight or Obese Individuals at Eighteen Years of Age Develop Pancreatic Adenocarcinoma at a Significantly Earlier Age. Co-author DOI 10.1155/2018/2380596↗
  47. Inhibition of endoplasmic-reticulum-stress-mediated autophagy enhances the effectiveness of chemotherapeutics on pancreatic cancer. Co-author DOI 10.1186/s12967-018-1562-z↗
  48. Integrated Genomic Characterization of Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1016/j.ccell.2017.07.007↗
  49. The CA19-9 and Sialyl-TRA Antigens Define Separate Subpopulations of Pancreatic Cancer Cells. Co-author DOI 10.1038/s41598-017-04164-z↗
  50. Gemcitabine/nab-paclitaxel as second-line therapy following FOLFIRINOX in metastatic/advanced pancreatic cancer-retrospective analysis of response. Co-author DOI 10.21037/jgo.2017.01.23↗

Grants 1

  1. Translational Research Grant: Aatur Singhi (diagnostic markers for mucinous pancreatic cysts) AWARD pancan:2016-aatur-singhi-md-phd-translational-research-grant-aatur-singh

Closest collaborators

The 25 strongest of 217 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Amer H. Zureikat · 27 shared papers, 2014–2026 · strength 3.71
  2. Alessandro Paniccia · 15 shared papers, 2021–2026 · strength 2.73
  3. Nathan Bahary · 21 shared papers, 2014–2023 · strength 2.13
  4. Randall E. Brand · 14 shared papers, 2017–2026 · strength 1.87
  5. Herbert J. Zeh · 19 shared papers, 2014–2022 · strength 1.60
  6. Ibrahim Nassour · 7 shared papers, 2021–2026 · strength 1.32
  7. Michael T. Lotze · 10 shared papers, 2015–2026 · strength 1.14
  8. Melissa Ellen Hogg · 11 shared papers, 2014–2022 · strength 1.09
  9. Asmita Chopra · 5 shared papers, 2021–2026 · strength 1.02
  10. Brian A. Boone · 11 shared papers, 2014–2022 · strength 0.95
  11. Samer S. AlMasri · 5 shared papers, 2022–2024 · strength 0.82
  12. Sebastiaan Ceuppens · 3 shared papers, 2025–2026 · strength 0.75
  13. Anwaar Saeed · 3 shared papers, 2025–2026 · strength 0.69
  14. Anirban Maitra · 6 shared papers, 2019–2022 · strength 0.61
  15. Brian B. Haab · 5 shared papers, 2017–2025 · strength 0.56
  16. Ying Huang · 5 shared papers, 2017–2025 · strength 0.56
  17. Christine Worthington · 2 shared papers, 2026 · strength 0.55
  18. Ralph H. Hruban · 4 shared papers, 2019–2026 · strength 0.54
  19. Andrew Eugene Hendifar · 4 shared papers, 2017–2026 · strength 0.54
  20. Lynette M. Smith · 2 shared papers, 2024–2026 · strength 0.54
  21. Pranav Murthy · 3 shared papers, 2020–2026 · strength 0.52
  22. Hussein H. Khachfe · 3 shared papers, 2023–2024 · strength 0.51
  23. Jiage Qian · 2 shared papers, 2025 · strength 0.49
  24. Siyang Zheng · 2 shared papers, 2025–2026 · strength 0.44
  25. Chanjuan Shi · 3 shared papers, 2021–2025 · strength 0.39

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.